GB1291281A - Improvements in pharmaceutical compositions - Google Patents
Improvements in pharmaceutical compositionsInfo
- Publication number
- GB1291281A GB1291281A GB04670/69A GB1467069A GB1291281A GB 1291281 A GB1291281 A GB 1291281A GB 04670/69 A GB04670/69 A GB 04670/69A GB 1467069 A GB1467069 A GB 1467069A GB 1291281 A GB1291281 A GB 1291281A
- Authority
- GB
- United Kingdom
- Prior art keywords
- sodium
- potassium
- citrate
- carbo
- penicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 3
- -1 arylmethyl penicillin Chemical class 0.000 abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- 229930182555 Penicillin Natural products 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 229940049954 penicillin Drugs 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000001509 sodium citrate Substances 0.000 abstract 2
- 229940038773 trisodium citrate Drugs 0.000 abstract 2
- 235000019263 trisodium citrate Nutrition 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- 229930186147 Cephalosporin Natural products 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000003139 buffering effect Effects 0.000 abstract 1
- 229940124587 cephalosporin Drugs 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 abstract 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract 1
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000019371 penicillin G benzathine Nutrition 0.000 abstract 1
- 229940056360 penicillin g Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 229910000027 potassium carbonate Inorganic materials 0.000 abstract 1
- 239000001508 potassium citrate Substances 0.000 abstract 1
- 229960002635 potassium citrate Drugs 0.000 abstract 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 abstract 1
- 235000011082 potassium citrates Nutrition 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000002278 tabletting lubricant Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 abstract 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
1291281 Antibiotic tablets PFIZER Ltd 18 March 1970 [20 March 1969] 14670/69 Heading A5B Pharmaceutical tablets for oral administration comprise a water-soluble salt of an α-carboxy-ester-substituted arylmethyl penicillin or arylmethyl cephalosporin and a water-soluble excipient which has a buffering action at a pH above 4.8. The water-soluble excipient may be sodium or potassium carbonate, bicarbonate, succinate, maleate or malonate, di-sodium or potassium hydrogen citrate, tri-sodium or potassium citrate and/or di-sodium or potassium hydrogen phosphate, preferably a mixture of di-sodium hydrogen citrate and tri-sodium citrate in a ratio of 1 to 5 by weight. The penicillin may be the sodium or potassium salt of a-[carbo-(2-isopropyl phenoxy)] benzyl-, α- [carbo-(5-indanyloxy)] benzyl- or α-[carbo-(4- carbomethoxy methyl-phenoxy)] benzyl penicillin. The tablets may also contain an anionic or nonionic surface active agent (e.g. sodium lauryl sulphate) a tabletting lubricant (e.g. magnesium stearate) and/or a protective colloid (e.g. polyvinyl pyrrolidone, polyethylene glycols or methyl cellulose).
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB04670/69A GB1291281A (en) | 1969-03-20 | 1969-03-20 | Improvements in pharmaceutical compositions |
| IL34089A IL34089A (en) | 1969-03-20 | 1970-03-16 | Pharmaceutical compositions containing penicillin or cephalosphorin derivatives |
| BE747656D BE747656A (en) | 1969-03-20 | 1970-03-19 | IMPROVED PHARMACEUTICAL COMPOSITIONS CONSISTING OF A WATER-SOLUBLE SALT OF AN ACTIVE ACID COMPOUND AND A WATER-SOLUBLE EXCIPIENT ( |
| DK138070AA DK128674B (en) | 1969-03-20 | 1970-03-19 | Process for the preparation of tablets containing water-soluble salts of α-carboxyester-substituted phenylmethyl-penicillins or α-carboxyester-substituted phenylmethyl-cephalosporins for oral administration. |
| FI700775A FI51653C (en) | 1969-03-20 | 1970-03-19 | A method of making an oral penicillin or cephalosporin tablet. |
| DE19702013039 DE2013039A1 (en) | 1969-03-20 | 1970-03-19 | Medicinal tablet for oral administration |
| NL707004004A NL143419B (en) | 1969-03-20 | 1970-03-20 | METHOD FOR PREPARING A PENICILLIN PREPARATION IN THE FORM OF A TABLET BY PROCESSING A WATER-SOLUBLE SALT OF A PENICILLIN AND A WATER-SOLUBLE BUFFER AGENT INTO A TABLET, AS WELL AS TABLETS THUS OBTAINED. |
| ES377725A ES377725A1 (en) | 1969-03-20 | 1970-03-20 | Improvements in pharmaceutical compositions |
| SE7003870A SE379284B (en) | 1969-03-20 | 1970-03-20 | |
| FR7010069A FR2035118B1 (en) | 1969-03-20 | 1970-03-20 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB04670/69A GB1291281A (en) | 1969-03-20 | 1969-03-20 | Improvements in pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1291281A true GB1291281A (en) | 1972-10-04 |
Family
ID=10045462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB04670/69A Expired GB1291281A (en) | 1969-03-20 | 1969-03-20 | Improvements in pharmaceutical compositions |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE747656A (en) |
| DE (1) | DE2013039A1 (en) |
| DK (1) | DK128674B (en) |
| ES (1) | ES377725A1 (en) |
| FI (1) | FI51653C (en) |
| FR (1) | FR2035118B1 (en) |
| GB (1) | GB1291281A (en) |
| IL (1) | IL34089A (en) |
| NL (1) | NL143419B (en) |
| SE (1) | SE379284B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424075A (en) * | 1991-03-27 | 1995-06-13 | Miles Inc. | Delivery system for enhanced onset and increased potency |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2115116C3 (en) * | 1970-03-27 | 1982-04-15 | Sankyo Co., Ltd., Tokyo | Lubricants and process for their manufacture |
| US3940483A (en) | 1971-02-05 | 1976-02-24 | E. R. Squibb & Sons, Inc. | Antibiotic compositions and method |
| US3969524A (en) * | 1974-08-13 | 1976-07-13 | Hoffmann-La Roche Inc. | Stable amoxicillin dosage form |
| JPS5329936A (en) * | 1976-08-31 | 1978-03-20 | Takeda Chem Ind Ltd | Antibiotic composition |
| EP0012495B1 (en) * | 1978-12-08 | 1983-06-22 | Beecham Group Plc | Pharmaceutical composition comprising a water soluble salt of amoxycillin and polyvinylpyrrolidone, and a vial containing a unit dose of said composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2438106A (en) * | 1944-06-09 | 1948-03-23 | Wyeth Corp | Peroral penicillin compositions |
| US2864744A (en) * | 1955-09-02 | 1958-12-16 | American Home Prod | Penicillin in solid dosage unit form |
| US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
| GB1276839A (en) * | 1968-08-02 | 1972-06-07 | Sandoz Products Ltd | Antibiotic compositions |
-
1969
- 1969-03-20 GB GB04670/69A patent/GB1291281A/en not_active Expired
-
1970
- 1970-03-16 IL IL34089A patent/IL34089A/en unknown
- 1970-03-19 DE DE19702013039 patent/DE2013039A1/en active Pending
- 1970-03-19 BE BE747656D patent/BE747656A/en not_active IP Right Cessation
- 1970-03-19 DK DK138070AA patent/DK128674B/en not_active IP Right Cessation
- 1970-03-19 FI FI700775A patent/FI51653C/en active
- 1970-03-20 FR FR7010069A patent/FR2035118B1/fr not_active Expired
- 1970-03-20 NL NL707004004A patent/NL143419B/en not_active IP Right Cessation
- 1970-03-20 ES ES377725A patent/ES377725A1/en not_active Expired
- 1970-03-20 SE SE7003870A patent/SE379284B/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424075A (en) * | 1991-03-27 | 1995-06-13 | Miles Inc. | Delivery system for enhanced onset and increased potency |
Also Published As
| Publication number | Publication date |
|---|---|
| DK128674B (en) | 1974-06-17 |
| FR2035118B1 (en) | 1974-08-30 |
| NL143419B (en) | 1974-10-15 |
| IL34089A0 (en) | 1970-05-21 |
| SE379284B (en) | 1975-10-06 |
| FI51653C (en) | 1977-03-10 |
| ES377725A1 (en) | 1972-10-16 |
| DE2013039A1 (en) | 1970-09-24 |
| FI51653B (en) | 1976-11-30 |
| IL34089A (en) | 1974-05-16 |
| NL7004004A (en) | 1970-09-22 |
| FR2035118A1 (en) | 1970-12-18 |
| BE747656A (en) | 1970-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES424533A1 (en) | Slow release pharmaceutical compositions | |
| PT91442A (en) | Controlled release dosage form - comprises matrix contg. high and low number average mol. wt. hydroxypropyl:methyl-cellulose | |
| GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
| GB1274271A (en) | Improvements in or relating to propionic acid derivatives | |
| MY104010A (en) | Pharmaceutical compositions. | |
| GB1291281A (en) | Improvements in pharmaceutical compositions | |
| GB1507418A (en) | Process for producing tablets and suppositories and a composition for use therein | |
| GB1274797A (en) | Effervescent tablets and powders | |
| GB1256968A (en) | ||
| CA2050970A1 (en) | Pharmaceutical compositions containing furan derivatives | |
| GB1464200A (en) | Pharmaceutical composition | |
| ES395533A1 (en) | Sustained released pharmaceutical compositions | |
| GB1291282A (en) | Improvements in pharmaceutical compositions | |
| GB1355985A (en) | Solid slow release preparation of prolonged action | |
| GB1403900A (en) | Pharmaceutical composition | |
| GB1202148A (en) | Pharmaceutical compositions | |
| GB9415048D0 (en) | Tablet | |
| GB1505738A (en) | Tabletting processes | |
| GB1381426A (en) | Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents | |
| ES447712A1 (en) | Pharmaceutical suspension for opaqing empty gelatin capsules | |
| GB1139991A (en) | Stabilized enzyme composition | |
| GB1357813A (en) | Effervescent composition for the treatment of heart diseases | |
| GB1327560A (en) | Effervescent pharmaceutical preparations | |
| GB1533243A (en) | Tablet formulation | |
| JPS5344617A (en) | Drug composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |